Department of Urology, All India Institute of Medical Sciences, New Delhi, India.
Urol Clin North Am. 2011 May;38(2):165-73. doi: 10.1016/j.ucl.2011.03.006.
Several centrally acting agents have shown potential to improve erectile function in men with ED. They still lack adequate data in efficacy and tolerability. Nasal formulations of apomorphine and bremelanotide seem to be the most likely candidates for future approval. They may play a role, specifically in men who fail phosphodiesterase 5 (PDE5) therapy, are unable to take PDE5 inhibitors because of side effects, or are on nitrate therapy. This article reviews the centrally acting agents and the data on their efficacy.
几种中枢作用药物已显示出改善 ED 男性勃起功能的潜力。它们在疗效和耐受性方面仍缺乏充分的数据。阿扑吗啡和布雷美尔肽的鼻用制剂似乎是未来最有可能获得批准的药物。它们可能在某些特定的患者中发挥作用，如 PDE5 治疗失败、因副作用而无法使用 PDE5 抑制剂、或正在使用硝酸盐治疗的患者。本文综述了中枢作用药物及其疗效数据。
